Skip to main content

Emphysema

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
NCT00670007 | PHASE 4 | INTERVENTIONAL

This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® intravenous (i.v). administration in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The long-term verification of a disease-modifying benefit of Zemaira® on the progression of emphysema will be assessed by volume-adjusted lung density, measured yearly by computed tomography (CT).

Trial Information
21 Sites
140 Participants
Recruiting
18 Years to 7 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
Adelaide,South Australia,Australia,5000
Study Site
Fitzroy,Victoria,Australia,3065
Study Site
Darlinghurst,Australia,2010
Study Site
Nedlands,Australia,6009
Study Site
New Lambton,Australia,2305
Study Site
Vancouver,British Columbia,Canada,V6J1S3
Study Site
Halifax,Nova Scotia,Canada,B3H3A7
Study Site
Toronto,Ontario,Canada,M5T2S8
Study Site
Praha 4 - Krc,Czech Republic,14059
Study Site
Arhus C,Denmark,8000
Study Site
Hellerup,Denmark,2900
Study Site
Tartu,Estonia,51014
Study Site
Oulu,Finland,90220
Study Site
Essen,Germany,45239
Study Site
Heidelberg,Germany,69126
Study Site
Nürnberg,Germany,90419
Study Site
Dublin,Ireland,9
Study Site
Krakow,Poland,31-066
Study Site
Warsaw,Poland,01-138
Study Site
Bucuresti,Romania,011026
Study Site
Malmo,Sweden,20502

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov